The largest database of trusted experimental protocols

Sinemet

Manufactured by MSD
Sourced in United States

Sinemet is a prescription medication used to treat the symptoms of Parkinson's disease. It contains a combination of two active ingredients, carbidopa and levodopa, which work together to improve motor function and reduce the severity of Parkinson's symptoms. Sinemet is available in different formulations and dosages, and its core function is to provide symptomatic relief for individuals living with Parkinson's disease.

Automatically generated - may contain errors

3 protocols using sinemet

1

Comparative Analysis of Parkinson's Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Carbidopa (CD, (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid), levodopa (LD, (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid), vanillin (4-hydroxy-3-methoxybenzaldehyde), acetonitrile (MeCN), ethanol (EtOH), dimethyl sulfoxide (DMSO, methylsulfinylmethane), methanol (MeOH), and hydrogen chloride (HCl) were purchased from Sigma-Aldrich (Milan, Italy). Brand drug Sinemet (200 mg levodopa, 50 mg Carbidopa, 35 mg excipients) was obtained from MSD (Rome, Italy), and its pharmaceutical alternative (generic drug) Hexal (200 mg levodopa, 50 mg Carbidopa, 194 mg excipients) was produced by Sandoz (Basel, Switzerland). All chemicals were of analytical reagent grade and used as received without any further purification. All solutions were prepared using water obtained from Milli-Q Water Purification System (resistivity ≥ 18 MΩcm) (Germany, www.merckmillipore.com).
+ Open protocol
+ Expand
2

Growth Hormone Secretion Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
After an overnight fast, an intravenous cannula was inserted. All provocation tests were performed in the morning hours with a 1-day interval between the two stimulation tests. To assess GH secretion, dopamine (Sinemet®, MSD, Whitehouse Station, NJ, USA; body weight more than 30 kg, 500 mg; body weight 15 to 30 kg, 250 mg; body weight less than 15 kg, 125 mg of L-dopa) was administered orally. Blood samples were drawn immediately before the medication and 30, 45, 60, 90, and 120 minutes later to obtain the serum GH concentration for each time point. Insulin (0.1 IU/kg) was administered as an intravenous bolus at time 0 to induce a fall in the blood glucose level to 50 mg/dL or less (or one-half of the baseline glucose level). Blood samples were obtained immediately before injection and at 15, 30, 45, 60, 90, and 120 minutes after injection. No patients were primed with sex steroids before the provocation tests.
+ Open protocol
+ Expand
3

Evaluation of Growth Hormone Deficiency

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patients who performed both baseline serum IGF-1 and IGFBP-3 and GHST were sampled the same day. The ITT was conducted, and the other GHST was performed using clonidine and Levodopa (L-dopa). L-dopa (body weight >30 kg, 500 mg; 15–30 kg, 250 mg; <15 kg, 125 mg; Sinemet®; MSD, Whitehouse Station, NJ, USA) and clonidine (0.125 mg/m2; Clonidine Hydrochloride®, Mylan Pharmaceuticals, Canonsburg, PA, USA) was orally administered after 8–10 h of overnight fasting without sex steroid priming. Blood samples were collected at 0, 30, 45, 60, 90, and 120 min. Regular insulin (0.1 IU/kg) was administered intravenously as a bolus at time 0 to stimulate hypoglycaemia (blood glucose <45 mg/dL or 56 . All height, weight, and BMI standard deviation score (SDS) were calculated using the 2017 Korean National Growth Charts52 (link). Serum IGF-1 levels were measured by an immunoradiometric assay (Immunotech, Marseille Cedex, France). The sensitivity of the assay was 2 ng/mL. The intra- and inter-assay coefficients of variations were less than 6.3% and 6.8%, respectively.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!